Cargando…

Prophylactic effects or withdrawal reactions? An analysis of time-to-event data from antidepressant relapse prevention trials submitted to the FDA

BACKGROUND: Relapse prevention trials build the scientific foundation for recommendation of antidepressant continuation and maintenance therapy. However, the validity of the evidence is disputed and may be biased due to withdrawal confounding. METHODS: We analysed survival curves from all antidepres...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hengartner, Michael P., Plöderl, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Discontinuing Psychotropic Medications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361519/ https://www.ncbi.nlm.nih.gov/pubmed/34394912 http://dx.doi.org/10.1177/20451253211032051

Ejemplares similares

How effective are antidepressants for depression over the long term? A critical review of relapse prevention trials and the issue of withdrawal confounding
por: Hengartner, Michael P.
Publicado: (2020)

Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum
por: Hengartner, Michael P., et al.
Publicado: (2020)

Conversations with clients about antidepressant withdrawal and discontinuation
por: Karter, Justin M.
Publicado: (2020)

The ‘patient voice’: patients who experience antidepressant withdrawal symptoms are often dismissed, or misdiagnosed with relapse, or a new medical condition
por: Guy, Anne, et al.
Publicado: (2020)

Clozapine discontinuation withdrawal symptoms in schizophrenia
por: Blackman, Graham, et al.
Publicado: (2021)

What it was like to stop an antidepressant
por: Stockmann, Tom
Publicado: (2019)

Outcomes of hyperbolic tapering of antidepressants
por: van Os, Jim, et al.
Publicado: (2023)

How user knowledge of psychotropic drug withdrawal resulted in the development of person-specific tapering medication
por: Groot, Peter C., et al.
Publicado: (2020)

Service-user efforts to maintain their wellbeing during and after successful withdrawal from antipsychotic medication
por: Larsen-Barr, Miriam, et al.
Publicado: (2021)

Patients’ attitudes to discontinuing not-indicated long-term antidepressant use: barriers and facilitators
por: Eveleigh, Rhona, et al.
Publicado: (2019)

Withdrawal effects confounding in clinical trials: another sign of a needed paradigm shift in psychopharmacology research
por: Cohen, David, et al.
Publicado: (2020)

Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review
por: Sørensen, Anders, et al.
Publicado: (2022)

Barriers to discontinuing antidepressants in patients with depressive and anxiety disorders: a review of the literature and clinical recommendations
por: Scholten, Willemijn, et al.
Publicado: (2020)

May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance
por: Fava, Giovanni A.
Publicado: (2020)

What I have learnt from helping thousands of people taper off antidepressants and other psychotropic medications
por: Framer, Adele
Publicado: (2021)

Barriers to stopping neuroleptic (antipsychotic) treatment in people with schizophrenia, psychosis or bipolar disorder
por: Moncrieff, Joanna, et al.
Publicado: (2020)

Polypharmacy-induced cognitive dysfunction and discontinuation of psychotropic medication: a neuropsychological case report
por: Valtonen, Jussi, et al.
Publicado: (2020)

Hamlet’s augury: how to manage discontinuation of mood stabilizers in bipolar disorder
por: Qureshi, Mutahira M., et al.
Publicado: (2021)

Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey
por: Reid Finlayson, Alistair J., et al.
Publicado: (2022)

Enduring neurological sequelae of benzodiazepine use: an Internet survey
por: Huff, Christy, et al.
Publicado: (2023)

Overdose and off-label psychotropic prescribing in patients with borderline personality disorder: A retrospective series
por: Ning, Anna Y, et al.
Publicado: (2023)

The prescription of psychedelic therapies in Australia and New Zealand: A brief survey of psychiatrists
por: Berger, Joshua J, et al.
Publicado: (2023)

The parable of the Therapeutic Goods Administration approval of esketamine (Spravato) in Australia
por: Lugg, William
Publicado: (2023)

Antidepressant withdrawal – the tide is finally turning
por: Hengartner, Michael P., et al.
Publicado: (2019)

What are the chances for personalised treatment with antidepressants? Detection of patient-by-treatment interaction with a variance ratio meta-analysis
por: Plöderl, Martin, et al.
Publicado: (2019)

Statistically Significant Antidepressant-Placebo Differences on Subjective Symptom-Rating Scales Do Not Prove That the Drugs Work: Effect Size and Method Bias Matter!
por: Hengartner, Michael P., et al.
Publicado: (2018)

Did the introduction and increased prescribing of antidepressants lead to changes in long-term trends of suicide rates?
por: Amendola, Simone, et al.
Publicado: (2020)

Time to relapse after treatment withdrawal for different biologics used to treat plaque psoriasis
por: Wang, Xiao-Yu, et al.
Publicado: (2020)

Predicting relapse after antidepressant withdrawal – a systematic review
por: Berwian, I. M., et al.
Publicado: (2017)

Estimating Risk of Antidepressant Withdrawal from a Review of Published Data
por: Horowitz, Mark Abie, et al.
Publicado: (2022)

Efficacy of new-generation antidepressants assessed with the Montgomery-Asberg Depression Rating Scale, the gold standard clinician rating scale: A meta-analysis of randomised placebo-controlled trials
por: Hengartner, Michael P., et al.
Publicado: (2020)

Astroglial Connexins Inactivation Increases Relapse of Depressive-like Phenotype after Antidepressant Withdrawal
por: Portal, Benjamin, et al.
Publicado: (2022)

Guidelines for the pharmacological acute treatment of major depression: conflicts with current evidence as demonstrated with the German S3-guidelines
por: Plöderl, Martin, et al.
Publicado: (2019)

Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
por: Sisi, Monia, et al.
Publicado: (2022)

The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA.
por: Olivier, Timothée, et al.
Publicado: (2022)

Tricyclic Antidepressant Withdrawal - A Case Report
por: Rajendra, P.N., et al.
Publicado: (1987)

Antidepressant-withdrawal mania - a case report
por: Magalhães, M., et al.
Publicado: (2021)

Mild Exercise Rescues Steroidogenesis and Spermatogenesis in Rats Submitted to Food Withdrawal
por: Santillo, Alessandra, et al.
Publicado: (2020)

Procedure for Organizing a Post-FDA-approval Evaluation of Antidepressants
por: Alemi, Farrokh, et al.
Publicado: (2022)

Safety of esketamine nasal spray: Analysis of post-marketing reports submitted to the FDA adverse event reporting system in the first year on the market
por: Gastaldon, C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8kuptf52pko742egb2mfi2nho9